Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.

ABSTRACT:

Background and purpose

Growing evidence implicates iron in the aetiology of gastrointestinal cancer. Furthermore, studies demonstrate that iron chelators possess potent anti-tumour activity, although whether iron chelators show activity against oesophageal cancer is not known.

Experimental approach

The effect of the iron chelators, deferoxamine (DFO) and deferasirox, on cellular iron metabolism, viability and proliferation was assessed in two oesophageal adenocarcinoma cell lines, OE33 and OE19, and the squamous oesophageal cell line, OE21. A murine xenograft model was employed to assess the effect of deferasirox on oesophageal tumour burden. The ability of chelators to overcome chemoresistance and to enhance the efficacy of standard chemotherapeutic agents (cisplatin, fluor

SUBMITTER: Ford SJ 

PROVIDER: S-EPMC3596639 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature